AnaptysBio, Inc. (ANAB) vs Stoke Therapeutics, Inc. (STOK)
AnaptysBio, Inc. and Stoke Therapeutics, Inc. are both Biotechnology companies. AnaptysBio, Inc. and Stoke Therapeutics, Inc. are of similar size ($1.6B and $1.6B). AnaptysBio, Inc. grew revenue faster over the last twelve months: 107.7% against −86.2%. AnaptysBio, Inc. has the higher net margin (−11.5% vs −753.6%) and the higher return on invested capital (0.00% vs −264.8%). Across the 15 metrics below, AnaptysBio, Inc. leads on 11 and Stoke Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | ANAB | STOK | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | 17.56% | (809.69%) | 0.00% |
| Net margin | (11.53%) | (753.60%) | 0.00% |
| Free cash flow margin | 1.90% | (654.92%) | 0.00% |
| Return on equity | (114.55%) | (61.10%) | (57.72%) |
| Return on assets | (7.13%) | (53.41%) | (49.22%) |
| Return on invested capital | 0.00% | (264.77%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack